AIM ImmunoTech Inc. AIM
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
AIM ImmunoTech Inc. (AIM) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to September 30, 2026 it had revenue of $91000 and net income of -$14M, a net margin of -15526.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -258%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About AIM ImmunoTech
AIM ImmunoTech is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $197000 in 2014 to $88000 in 2025, a decline of about 7.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 237% over three years (dilution for shareholders). It spends 4459% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $91000 | $88000 | $170000 | $202000 | $141000 | $135000 | $163000 | $140000 | $367000 | $437000 | $92000 |
| Net income | -$14M | -$14M | -$17M | -$29M | -$19M | -$19M | -$14M | -$9M | -$10M | -$8M | -$8M |
| Free cash flow | — | — | -$15M | — | -$16M | -$14M | -$10M | -$9M | -$11M | -$8M | -$8M |
| EPS (diluted) | $-0.35 | $-0.34 | $-1.24 | $-2.40 | $-1.60 | $-1.60 | $-1.80 | $-10.32 | $-39.08 | $-51.04 | $-59.84 |
| Net margin | -15526.4% | -15861.4% | -10188.2% | -14337.6% | -13790.8% | -14168.1% | -8834.4% | -6717.1% | -2677.7% | -1889.9% | -8154.3% |
| ROIC | — | — | -737.1% | -230.2% | -40.0% | -26.1% | -18.8% | -61.7% | -112.2% | -85.6% | -70.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $4.25, 2860% above the current price; targets range from $1.50 to $7.00; the consensus rating is “none”; expected EPS is $-0.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is AIM ImmunoTech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does AIM ImmunoTech pay a dividend?
Not currently.
Is AIM ImmunoTech a good stock to buy?
We do not give buy or sell advice. AIM ImmunoTech scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.